All Stories

Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.

Mar 17, 2025 - 13:18
 0
Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.
Read More

Tags:

Previous Article

Citygate diversifies with launch of new leasing business

Next Article

Q Energy to build 200MW solar PV in Spain

Related Posts

Pfizer to test Summit's white-hot bispecific with ADCs

Pfizer to test Summit's white-hot bispecific with ADCs

Feb 24, 2025  0

NIH grants powered $94B in economic activity in 2024 and supported more than 400,000 jobs: report

NIH grants powered $94B in economic activity in 2024 an...

Mar 11, 2025  0

FDA amplifies BD atherectomy safety alert following 4 deaths

FDA amplifies BD atherectomy safety alert following 4 d...

Feb 10, 2025  0